Johnson & Johnson (JNJ) Stock May Be 31% Below Fair Value On Talc Settlement

Johnson & Johnson stock has delivered a 76.0% return over the past five years, while a Discounted Cash Flow (DCF) intrinsic value estimate currently points to the shares trading at roughly a 31.2% discount to that model. Set against that, the broader valuation checks lean cautious on the stock rather than flagging it as a clear bargain.

• A 76.0% return over five years suggests Johnson & Johnson has already rewarded long term holders, so new investors may be asking how much upside could be left from here.
• Progress in areas such as oncology and robotic surgery can support expectations for future cash flows, while the proposed US$5.5b talc settlement and ongoing litigation risk may weigh on how investors price those cash flows.
• On Simply Wall St’s broader checks, Johnson & Johnson screens as undervalued on 2 of 6 valuation tests, which points to a stock that does not look unambiguously cheap on every yardstick.

The issue now is whether Johnson & Johnson’s recent share price strength already reflects most of the upside implied by the intrinsic value estimate, or if the current discount leaves a meaningful margin of safety.

Johnson & Johnson delivered 62.6% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is Johnson & Johnson a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Johnson & Johnson is worth today based on the cash it is expected to generate in the future. On this view, the company’s latest twelve month free cash flow sits at about $21.7b, with the model assuming that cash flows continue to grow from here rather than shrink. Feeding those projections into a two stage DCF produces an estimated intrinsic value of about $387.88 per share in dollar terms.

Set against the current share price, that intrinsic value implies Johnson & Johnson screens as roughly 31.2% undervalued. The proposed US$5.5b talc settlement helps explain why the market may be applying a discount, since it highlights ongoing legal risk even as cash generation remains solid.

On balance, the DCF output indicates that Johnson & Johnson stock may be trading below the value implied by the cash flows analysts currently expect it to produce.

Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 31.2%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson.

Is Johnson & Johnson Fairly Priced on Earnings?

P/E suits Johnson & Johnson because earnings remain a central anchor for how investors look at large pharmaceutical stocks. Right now the stock trades on a P/E of about 30.6x, compared with the Pharmaceuticals industry average of roughly 15.5x and a peer group average of about 29.1x. That puts Johnson & Johnson at a premium to the wider sector but only slightly above close peers.

The tailored fair P/E ratio for Johnson & Johnson sits at around 29.4x, which is very close to where the stock is actually trading. The small gap between the current 30.6x and this fair ratio suggests the market already prices in the company’s mix of established products, pipeline prospects and legal risks such as the proposed US$5.5b talc settlement. On this framework, there is no clear signal that the stock is either sharply cheap or stretched.

On the P/E yardstick, Johnson & Johnson appears to be trading at roughly a fair valuation level compared with its earnings power and peers.

See what the numbers say about this price — find out in our valuation breakdown.

The Johnson & Johnson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Johnson & Johnson pick up where this valuation puzzle leaves off and spell out what growth, margin and earnings paths would need to play out for the stock to be worth significantly more or less than today’s price, all on the Community page. Rather than focusing on a single multiple or model, each narrative lays out the assumptions behind its fair value so you can compare them with Johnson & Johnson's results over time.

Community views on Johnson & Johnson sit quite far apart, with one camp leaning into the oncology and MedTech build out and the other keeping a close eye on policy and legal risk.

Bull case: 13% undervalued

"Heavy investment in drug discovery and deal making, with more than US$32b in 2025 allocated to R&D and M&A plus 51 approvals, 32 submissions and 11 new Phase III programs, sets up a sizeable pipeline that could feed future revenue and help sustain or expand net margins as higher value products mature..."

Read the full Bull Case to see why Johnson & Johnson could be undervalued

Bear case: 5% overvalued

"Loss of exclusivity for STELARA and the impact of biosimilar competition could significantly erode revenue from one of Johnson & Johnson's major products..."

Read the full Bear Case to see why Johnson & Johnson could be overvalued

Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying!

The Bottom Line

For Johnson & Johnson, the Discounted Cash Flow (DCF) intrinsic value estimate still points to a meaningful valuation discount, while the earnings multiple view looks about right compared with peers. That split likely reflects how the DCF leans on long term cash flow strength, while the market multiple keeps a closer eye on sentiment around litigation and patent risk. Broader valuation checks remain weak despite the intrinsic value signal, so the key question is whether the current discount compensates for those legal and product concentration risks or instead reflects them accurately.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com